Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.47 |
| ▸ | ANPEP | P15144 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.41 |
| ▸ | MMP8 | P22894 | 5/20 | 0.41 |
| ▸ | MMP13 | P45452 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691691 | 1.00 | MMP2 (0.47) | MMP2ANPEPMMP9MMP8MMP13 | |
| SCHEMBL13403515 | 0.90 | MMP2 (0.47) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL13403495 | 0.90 | MMP2 (0.47) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL13403498 | 0.90 | MMP2 (0.46) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL13403432 | 0.85 | MMP2 (0.42) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL200851 | 0.83 | FKBP1A (0.46) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL13403494 | 0.83 | PRSS1 (0.40) | MMP2ANPEPPKM | |
| SCHEMBL13403522 | 0.82 | MMP2 (0.40) | MMP2ANPEPPKMFKBP1A | |
| SCHEMBL13403516 | 0.81 | MMP2 (0.40) | MMP2ANPEP | |
| SCHEMBL13403521 | 0.81 | MMP2 (0.40) | MMP2ANPEPMMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | MMP2 1855/4885ANPEP 418/4885MMP9 1667/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | MMP2 1277/4885ANPEP 160/4885MMP9 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.